Phase I trial of Actimab-M starts for relapsed and/or refractory myeloma patients

The US biopharmaceutical company, Actinium Pharmaceuticals Inc., has announced it is starting a Phase I trial of its drug Actimab-M for relapsed and/or refractory myeloma patients. Actimab-M is the anti-CD33 antibody, HuM-195, conjugated to the radioactive compound actinium 225 and has been used in other haematological malignancies including acute myeloid leukaemia. Studies show that CD33…

Details